[1]王玲,倪兆慧,何奔.对比剂肾病研究进展[J].介入放射学杂志,2007,(01):66.
 WANG Ling,NI Zhao-hui,HE Beng.The research progress of contrast media induced nephropathy[J].journal interventional radiology,2007,(01):66.
点击复制

对比剂肾病研究进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2007年01期
页码:
66
栏目:
综述
出版日期:
2007-01-15

文章信息/Info

Title:
The research progress of contrast media induced nephropathy
作者:
王玲倪兆慧何奔
200002上海交通大学医学院附属仁济医院肾内科(王玲);心内科(倪兆慧、何奔)
Author(s):
WANG LingNI Zhao-huiHE Beng.
Department of Nephrology,Renji Hospital School of Medicine Shanghai Jiaotong University,Shanghai200002,China
关键词:
对比剂相关肾病病理生理危险因素预测预防
分类号:
R692.39;R692.5
文献标志码:
A
摘要:
随着造影技术在临床的广泛应用,特别是在高龄、有严重合并症患者中的应用,如糖尿病、肾功能衰竭、心功能衰竭、容量不足等患者,使对比剂肾病(contrast induced nephropathy,CIN)成为医院获得性肾功能衰竭的第三大主要原因,占发病率的11%。本文主要介绍有关CIN病理生理学方面的实验室研究进展、CIN危险因子等方面的重要临床资料的研究进展以及预防策略及各种药物治疗的研究进展。

参考文献/References:

[1]Nash K,Hafeez A,Hou S.Hospital-acquired renal insufficiency[J].Am J Kidney Dis,2002,39:930-936.
[2]McCullough PA,Sandberg KR.Epidemiology of contrast-induced nephropathy[J].Rev Cardiovasc Med,2003,4(suppl5):S3-S9.
[3]Thomsen HS,Morcos SK.Contrast media and the kidney.Euro-pean Society of Urogenital Radiology(ESUR)guidelines[J].Br J Radiol,2003,76:513-518.
[4]倪钧,沈卫峰,张瑞岩,等.非离子型对比剂在肾动脉介入治疗中的安全性研究[J].介入放射学杂志,2004,13:137-139.
[5]Denton KM,Whweta A,Anderson WP.Preglomerular and post-glomerular resistance responses to different levels of sympathetic activation by hypoxia[J].J Am Soc Nephrol,2002,13:27-34.
[6]Prasad PV,Priatna A,Spokes K,et al.Changes in intra-renal oxygenation as evaluated by BOLD MRI in a rat kidney model for radiocontrast nephropathy[J].J Magn Reson Imaging,2001,13:744-747.
[7]Nircis SK.Prevention of contrast media nephrotoxicity-the story so far[J].Clin Radiol,2004,59:381-389.
[8]Rihal CS,Textor SC,Grill DE,et al.Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention[J].Circulation,2002,105:2259-2264.
[9]National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Am J Kidney Dis,2002,39:S1-266.
[10]Szczech LA,Best P,Crowley E,et al.Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation[J].Circulation,2002,105:2253-2258.
[11]Mehran R,Aymong ED,Nikolsky E,et al.A simple risk score for prediction of contrast induced nephropathy after percuatneous coronary intervention:development and initial validation[J].J Am Coll Cardiol,2004,44:1393-1399.
[12]Sherwin PF,Cambron R,Johnson JA,et al.Contrast dose-to-creatinine clearance ratio as a potential indicator of risk for radiocontrast induced nephropathy:correlation of D/CrCl with area under the contrast-concentration-time curve using iodixanol[J].Invest Radiol,2005,40:598-603.
[13]Thomsen HS.How to avoid CIN:guidelines from the European society of Urogenital Radiology[J].Nephrol Dial Transplant,2005,20:i18-i22.
[14]Mueller C,Buerlle G,Buettner,et al.Prevention of contrast media-associated nephropathy:randomized comparison of2hydration regimens in1620patients undergoing coronaryangioplasty[J].Arch Intern Med,2002,162:329-336.
[15]Davidson CJ,Laskey WK,Hemiller JB,et al.Randomized trial of contrast media utilization in high-risk PTCA:the COURT trial[J].Circulation,2000,101:2172-2177.
[16]Kohemainen H,soiva M.Comparison of Xenetrix300and Visi-paque320in patients with renal failure[J].Eur Radiol,2003,13:B32.
[17]李美花,范利.老年人对比剂肾病及临床相关因素分析[J].中国老年学杂志,2005,25:649-651.
[18]徐红,陈丽萌,李学旺.肾功能不全患者发生对比剂肾病的危险因素和预后[J].中国医学科学院学报,2005,27:232-236.
[19]Ochoa A,Pellizzon G,Addala S,et al.Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention[J].J Interv Cardiol,2004,17:159-165.
[20]Baker CS,Wragg A,Kumar S,et al.A rapid protocol for the prevention of contrast-induced renal dysfunction:the RAPPID study[J].J Am Coll Cardiol,2003,41:2114-2118.
[21]Gulel O,Keles T,Eraslan H,et al.Prophylactic Acetylcysteine Usage for Prevention of Contrast Nephropathy after Coronary Angiography[J].J Cardiovasc Pharmacol,2005,46:464-467.
[22]Kshirsagar AV,Poole C,Mottl A,et al.N-acetylcysteine for the prevention of radiocontrast induced nephropathy:a meta-analysis of prospective controlled trials[J].J Am Soc Nephrol,2004,15:761-769.
[23]Ix JH,McCulloch CE,Chertow GM.Theophylline for the pre-vention of radiocontrast nephropathy:a meta-analysis[J].Nephrol Dial Transplant,2004,19:2747-2753.
[24]Bagshaw SM,Ghali WA.Theophylline for prevention of contrast-induced nephropathy:a systematic review and meta-analysis[J].Arch Intern Med,2005,165:1087-1093.
[25]Marenzi G,Bartorelli AL.Hemofiltration in the prevention of radiocontrast agent induced nephropathy[J].Minerva Anestesiol,2004,70:189-191.
[26]Voget B,Ferrari P,Schonholzer C,et al.Prophylactic hemo-dialysis after radiocontrast media in patients with renal insufficiency is potentially harmful[J].Am J med,2001,111:692-698.
[27]Marenzi G,Bartorelli AL.Recent advances in the prevention of radiocontrast-induced nephropathy[J].Curr Opin Crti Care,2004,10:505-509.
[28]McCullough PA熏Soman SS.Contrast-induced nephropathy[J].Crit Care Clin,2005,21:261-280.

备注/Memo

备注/Memo:
收稿日期:2005-11-28
更新日期/Last Update: 2007-01-15